AllinkBio Raises $42M for Antibody Therapies

Allink Biotherapeutics, a China-based developer of advanced antibody-based therapies, has successfully closed a $42 million Series A funding round. This significant capital infusion is earmarked to propel the global clinical advancement of its innovative bispecific antibody and antibody-drug conjugate (ADC) programs, targeting critical unmet needs in oncology and immunology.

The financing was spearheaded by Lanchi Ventures, a prominent early-stage technology investor. The round saw robust participation from a distinguished group of new investors, including Yuanbio Venture Capital, Legend Capital, and C&D Emerging Industry Equity Investment. Existing backers, Gaorong Ventures and Med-Fine Capital, also demonstrated continued confidence through their reinvestment.

This funding marks a pivotal moment for AllinkBio, which has rapidly progressed its lead asset, ALK201, from inception to clinical development within a little over a year. The company's CEO, Hui Feng, Ph.D., highlighted the strategic importance of this capital in accelerating the development of its diverse pipeline, which includes next-generation ADCs and bispecific antibodies. The funds will support Phase 1 studies for ALK201 and ALK202 in Australia, the United States, and China, alongside the expansion of its proprietary technology platforms and the addition of new assets.

The oncology therapeutics market, particularly the targeted therapy segment, is experiencing substantial growth, driven by advancements in drug delivery mechanisms like ADCs. The global ADC market alone is projected to reach tens of billions of dollars in the coming years, fueled by increasing R&D investments and a growing pipeline of candidates. AllinkBio's focus on novel bispecific antibodies and advanced ADC designs positions it to capitalize on this expanding opportunity, aiming to deliver first-in-class and best-in-class treatments.

Lanchi Ventures commented on AllinkBio's exceptional execution speed and scientific rigor, noting the company's capability to translate complex scientific findings into tangible clinical applications. This aligns with the broader trend of venture capital firms actively seeking out biotech innovators with strong preclinical data and clear development pathways, especially in areas with high therapeutic potential like targeted cancer therapies.

Gaorong Ventures, an existing investor, reaffirmed its commitment, citing the company's impressive progress in both platform development and pipeline advancement since their initial investment. Similarly, Med-Fine Capital, the lead investor in the company's angel round, expressed strong conviction in Dr. Feng and his team's ability to advance two promising ADC candidates into clinical stages within an ambitious timeframe, underscoring the company's high competitiveness.

With this substantial Series A financing, Allink Biotherapeutics is strategically positioned to enhance its global footprint and achieve significant milestones. The company's dual focus on innovative bispecific antibody technology and cutting-edge ADC development, coupled with a clear clinical development strategy, signals a strong trajectory for growth and a commitment to addressing critical patient needs worldwide.